Tag Archives: Aurobindo Pharma

The transaction underpins Novartis’s strategy of achieving sustainable and profitable growth in the US in the long term. Swiss pharmaceutical company Novartis announced the divestment of its dermatology and generic tablet portfolios of Sandoz US to India’s Aurobindo Pharma for a $900 million (CHF870 million) cash payment. A possible performance-related payment of $100 million could be added to the purchase price, the...

Read More »